A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma
Status:
Suspended
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of a single infusion of
OPD5 before Autologous Stem Cell Transplant in patients with RRMM. The study will evaluate
increasing doses of OPD5 to find the best dose and to assess any side effects. Each patient
will be assigned to a dose cohort of 3-6 patients to receive one single dose of OPD5. Each
patient will be hospitalized for about 14 days from the OPD5 infusion and then have monthly
visits to the clinic for 3 months and then every third month until disease progression or
starting new myeloma treatment, maximum up to 2 years.